Phelps in the news about Medibio, page-4

I agree with you, the foundation years of this company are complete and the commercialisation run from here begins.

The market cap is partly to blame by the capitulation selling from the last capital raise at 36c in October. Since then the company has signed commercial trials, obtained CE and TGA mark and are about to launch their consumer offering along with potentially adding more blue chip corporate clients.

MEB most importantly is on the verge of FDA submission for the worlds first cleared objective biometrics monitoring solution for mental illness, backed by years of scientific research. This will be a key inflection point for the company and make this a massive takeover target once approved.

The clinicians and scientific board of this company speak volumes, and the CEO who joined last year seems to have made real inroads yet the share price hasn't responded. The market cap is peanuts, their data set is worth more than the current share price imo.

The only reasonable objection to this investment is the cash burn, but this is necessary to establish a global presence. Medibio are funded until 2019 regardless and by then FDA approval will be imminent (or granted as it could well be fast tracked) and the horse would have bolted.

This is a classic medtech play and I'm big fan of the sector. Currently invested in RAP and held MYQ all the way for a 10+ bagger last year. Also was in PCK since RTO. The reward outweighs the downside.